NSE: AJANTPHARM | BSE: 532331

Falling Comet

Download real time

2510.80 -64.90 (-2.52%)

27.95% Fall from 52W High

128.8K NSE+BSE Volume

NSE 30 May, 2025 3:31 PM (IST)

31,362.9

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Search Inside the pdf :

Ajanta Pharma Ltd.

01 May 2025, 12:00AM

2510.80

-2.52%

Ajanta Pharma (HOLD): A New Dawn of Culture

Hold: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Mix set of earnings where sales/EBITDA/PAT reported 5%/3%/10% above estimates; EBITDA margin reported 60 bps below estimates

Promoters pledged 1.44% of shares in last quarter. Total pledge stands at 12.61% of promoter holdings

Ajanta Pharma Ltd.

01 May 2025, 12:00AM

2510.80

-2.52%

Elevated cost to keep a check on margins

Sell: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Ajanta Pharma’s Q4FY25 result was in line with our expectations. Revenue growth of 11% YoY was primarily driven by India and US businesses while Africa institutional biz continues to be a drag (-54.1% YoY).

Promoters pledged 1.44% of shares in last quarter. Total pledge stands at 12.61% of promoter holdings

Ajanta Pharma Ltd.

31 Jan 2025

2510.80

-2.52%

Ajanta Pharma (SELL): Entering newer therapies to result in higher costs

Sell: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

AJP reported in-line earnings, sales were 3.6% below estimates, while EBITDA/PAT reported 1%/3% above our estimates

Promoters pledged 1.44% of shares in last quarter. Total pledge stands at 12.61% of promoter holdings

Ajanta Pharma Ltd.

30 Jan 2025

2510.80

-2.52%

India/Asia drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered a marginally better-than-expected performance in 3QFY25. It has continued to outperform in the Domestic Formulation (DF) market during this quarter.

Ajanta Pharma Ltd. has an average target of 2992.50 from 4 brokers.

Ajanta Pharma Ltd.

11 Dec 2024

2510.80

-2.52%

Ajanta Pharma (SELL): No incremental triggers; valuation expensive

Sell: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

At our virtual conference AJP said it is not looking to venture into newer therapies in India in the next 1-2 years due to hefty valuations

Ajanta Pharma Ltd. has an average target of 2992.50 from 4 brokers.

Ajanta Pharma Ltd.

11 Nov 2024

2510.80

-2.52%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

28 Oct 2024

2510.80

-2.52%

Branded generics drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered in-line performance in 2QFY25. Asia/Africa (47% of sales) grew strongly at 32% YoY in 2QFY25 due to superior execution and partly on the low base of the past year.

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

31 Jul 2024

2510.80

-2.52%

Ajanta Pharma

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Promoters pledged 1.44% of shares in last quarter. Total pledge stands at 12.61% of promoter holdings

Ajanta Pharma Ltd.

30 Jul 2024

2510.80

-2.52%

Branded generics drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered better-than-expected 1QFY25 performance, led by a superior show in the branded Africa segment, lower raw material costs, and controlled other expenses.